Traders should watch for FDA acceptance of the NDA and any updates on the review timeline. A Priority Review Voucher (PRV) award upon approval could provide a non-dilutive cash infusion. Monitor for potential partnership or financing announcements to fund commercialization.
Price Chart
Executive Summary
Monopar Therapeutics initiated the rolling submission of a New Drug Application (NDA) for ALXN1840 (tiomolibdate choline) in Wilson disease to the FDA. If accepted and approved, ALXN1840 would be the first therapy with a novel mechanism of action for Wilson disease in decades. The filing is a significant regulatory catalyst for this clinical-stage biotech, supported by Phase 3 data and FDA designations including Rare Pediatric Disease (RPD) status that could yield a Priority Review Voucher.
Key Facts
- Rolling NDA submission initiated for ALXN1840 in Wilson disease
- Phase 3 trial met primary endpoint with rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks
- 645 patient-years of follow-up in 266 patients with well-characterized safety profile
- Fast Track, Orphan Drug, and Rare Pediatric Disease (RPD) designations granted by FDA
- RPD designation provides potential for a pediatric Priority Review Voucher upon NDA approval
- If approved, ALXN1840 would be the first novel mechanism therapy for Wilson disease in decades
Financial Impact
No financial figures disclosed; valuation impact depends on NDA acceptance and eventual approval, with potential for significant upside given orphan drug market and PRV value
Risk Factors
- FDA may not accept the NDA for filing or may issue a Complete Response Letter
- Clinical-stage company with no approved products; requires additional capital to fund operations
- Competition from existing Wilson disease therapies could limit market adoption
- RPD voucher program may face regulatory changes or expiration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-024041 |
| Exhibit: ex_991049.htm | 0001437749-26-024041 |
| Document: 0001437749-26-024041-index-headers.html | 0001437749-26-024041 |
| Document: 0001437749-26-024041-index.html | 0001437749-26-024041 |
| Document: 0001437749-26-024041.txt | 0001437749-26-024041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $70.68 (+11.17%) |
Oct 1, 2026 25d ago | 144 | $77.97 | awaiting T+60 | — | $70.68 (−9.35%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $70.68 (−36.85%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $70.68 (−36.83%) |
Aug 25, 2026 8w ago | 144 | $113.72 | awaiting T+60 | — | $70.68 (−37.85%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $70.68 (−38.49%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $70.68 (−38.49%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.68 (−37.16%) |
Jul 22, 2026 13w ago | Press Release | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.68 (−37.16%) |
Jun 30, 2026 17w ago | 8-K | $92.59 $89.38 | ▼ −3.47% | ▼ −7.03% | $70.68 (−23.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers